An unusual fusion gene EML4-ALK in a patient with congenital mesoblastic nephroma

Genes Chromosomes Cancer. 2021 Dec;60(12):837-840. doi: 10.1002/gcc.22990. Epub 2021 Aug 22.

Abstract

Congenital mesoblastic nephroma (CMN), the most common renal tumor of infancy, is a mesenchymal neoplasm histologically classified into classic, cellular, or mixed types. Most cellular CMNs harbor a characteristic ETV6-NTRK3 fusion. Here, we report an unusual congenital mesoblastic nephroma presenting in a newborn boy with a novel EML4-ALK gene fusion revealed by Anchored Multiplex RNA Sequencing Assay. The EML4-ALK gene fusion expands the genetic spectrum implicated in the pathogenesis of congenital mesoblastic nephroma, with yet another example of kinase oncogenic activation through chromosomal rearrangement. The methylation profile of the tumor corresponds with infantile fibrosarcoma showing the biological similarity of these two entities.

Keywords: ALK fusion; RNAseq; congenital mesoblastic nephroma; infantile fibrosarcoma; methylation profiling.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • ETS Translocation Variant 6 Protein
  • Fibrosarcoma / diagnosis
  • Fibrosarcoma / genetics*
  • Fibrosarcoma / pathology
  • Humans
  • In Situ Hybridization, Fluorescence
  • Infant, Newborn
  • Male
  • Nephroma, Mesoblastic / diagnosis
  • Nephroma, Mesoblastic / genetics*
  • Nephroma, Mesoblastic / pathology
  • Oncogene Proteins, Fusion / genetics*
  • Proto-Oncogene Proteins c-ets / genetics*
  • RNA-Seq
  • Receptor, trkC / genetics*
  • Repressor Proteins / genetics*

Substances

  • EML4-ALK fusion protein, human
  • NTRK3 protein, human
  • Oncogene Proteins, Fusion
  • Proto-Oncogene Proteins c-ets
  • Repressor Proteins
  • Receptor, trkC